Evidence map›Paper›PMID 38655860›Full record

ArticleJournal of proteome research2024

Establishing Personalized Blood Protein Reference Ranges Using Noninvasive Microsampling and Targeted Proteomics: Implications for Antidoping Strategies.

Vincent R Richard, Georgia Mitsa, Azad Eshghi, Daria Chaplygina, Yassene Mohammed, David R Goodlett, Rene P Zahedi, Mario Thevis, Christoph H Borchers

Abstract read
In one paragraph

Article in Journal of proteome research, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Review
  5. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Vincent R RichardSegal Cancer Proteomics Centre, Lady Davis Institute for Medical Research, Jewish General Hospital, Montréal, Quebec H3T 1E2, Canada.
Georgia MitsaSegal Cancer Proteomics Centre, Lady Davis Institute for Medical Research, Jewish General Hospital, Montréal, Quebec H3T 1E2, Canada.
Azad EshghiUniversity of Victoria-Genome BC Proteomics Centre, Victoria, British Columbia V8Z 7X8, Canada.
Daria ChaplyginaSegal Cancer Proteomics Centre, Lady Davis Institute for Medical Research, Jewish General Hospital, Montréal, Quebec H3T 1E2, Canada.
Yassene MohammedCenter for Proteomics and Metabolomics, Leiden University Medical Center, Leiden 2333 ZC, The Netherlands.ORCID 0000-0003-3265-3332
David R GoodlettUniversity of Victoria-Genome BC Proteomics Centre, Victoria, British Columbia V8Z 7X8, Canada.
Rene P ZahediManitoba Centre for Proteomics and Systems Biology, Winnipeg, Manitoba R3E 3P4, Canada.ORCID 0000-0002-4960-5460
Mario ThevisInstitute of Biochemistry, Center for Preventive Doping Research, German Sport University Cologne, Cologne 50933, Germany.
Christoph H BorchersSegal Cancer Proteomics Centre, Lady Davis Institute for Medical Research, Jewish General Hospital, Montréal, Quebec H3T 1E2, Canada.ORCID 0000-0003-2394-6512

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

To prevent doping practices in sports, the World Anti-Doping Agency implemented the Athlete Biological Passport (ABP) program, monitoring biological variables over time to indirectly reveal the effects of doping rather than detect the doping substance or the method itself. In the context of this program, a highly multiplexed mass spectrometry-based proteomics assay for 319 peptides corresponding to 250 proteins was developed, including proteins associated with blood-doping practices. "Baseline" expression profiles of these potential biomarkers in capillary blood (dried blood spots (DBS)) were established using multiple reaction monitoring (MRM). Combining DBS microsampling with highly multiplexed MRM assays is the best-suited technology to enhance the effectiveness of the ABP program, as it represents a cost-effective and robust alternative analytical method with high specificity and selectivity of targets in the attomole range. DBS data were collected from 10 healthy athlete volunteers over a period of 140 days (28 time points per participant). These comprehensive findings provide a personalized targeted blood proteome "fingerprint" showcasing that the targeted proteome is unique to an individual and likely comparable to a DNA fingerprint. The results can serve as a baseline for future studies investigating doping-related perturbations.

Indexed as

Blood ProteinsDoping in SportsDried Blood Spot TestingProteomicsAdultAthletesBiomarkersFemaleHumansMaleMass SpectrometryProteomeReference ValuesSubstance Abuse DetectionBiomarkersBlood ProteinsProteomeblood-doping practicesdried blood spotsmicrosamplingmultiple reaction monitoringquantitative proteomicstargeted proteome profile

Identifiers

PMID38655860
PMCPMC11077581

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.